Vyant Bio (VYNT) Misses Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vyant Bio Reports Second Quarter 2021 Results and Provides Strategic Business Updates
August 16, 2021 4:01 PM EDTStrategic Highlights
Received an issued US Patent titled High Throughput Optical Assay of Human Mixed Cell Population Spheroids by the United States Patent and Trademark Office (USPTO). The patent covers the use of spheroids and organoids for drug discovery.Entered into a strategic collaboration with Ordas Bio and Cellaria, Inc. to execute an integrated model for rapid iteration of therapeutic design using artificial intelligence (AI) and human-derived in vitro avatar clinical trials to enable the design, development, and testing of potential therapeutics on targeted... More